New drug DF5112 put to the test in healthy volunteers
NCT ID NCT07232121
First seen Nov 18, 2025 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This early-stage study tests a new drug, DF5112, in 48 healthy adults to see if it is safe and how the body handles it. Participants receive a single dose of the drug or a placebo and are monitored for about a week in a clinic, with follow-up visits for a month. The goal is to gather information on side effects, drug levels in the blood, and immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Scientia Clinical Research Ltd
RECRUITINGSydney, New South Wales, 2031, Australia
Contact
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.